R1 RCM Inc. (NASDAQ:RCM - Free Report) - Leerink Partnrs issued their Q2 2024 EPS estimates for R1 RCM in a research report issued on Monday, April 29th. Leerink Partnrs analyst M. Cherny anticipates that the healthcare provider will earn ($0.01) per share for the quarter. Leerink Partnrs has a "Outperform" rating on the stock. The consensus estimate for R1 RCM's current full-year earnings is ($0.05) per share. Leerink Partnrs also issued estimates for R1 RCM's Q3 2024 earnings at $0.03 EPS, FY2024 earnings at $0.09 EPS, FY2025 earnings at $0.24 EPS, FY2027 earnings at $0.59 EPS and FY2028 earnings at $0.84 EPS.
A number of other brokerages also recently weighed in on RCM. KeyCorp reaffirmed a "sector weight" rating on shares of R1 RCM in a research note on Wednesday, April 10th. Barclays reaffirmed an "equal weight" rating and issued a $14.00 target price on shares of R1 RCM in a research note on Wednesday, February 28th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $19.00 target price on shares of R1 RCM in a research note on Thursday, March 7th. Cantor Fitzgerald reissued an "overweight" rating and set a $20.00 price target on shares of R1 RCM in a research note on Wednesday, April 10th. Finally, Morgan Stanley reissued an "overweight" rating and set a $17.00 price target on shares of R1 RCM in a research note on Tuesday, March 26th. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $16.87.
Get Our Latest Research Report on R1 RCM
R1 RCM Trading Up 0.6 %
Shares of R1 RCM stock traded up $0.07 on Wednesday, reaching $12.36. The stock had a trading volume of 2,064,875 shares, compared to its average volume of 3,551,034. R1 RCM has a 1 year low of $8.87 and a 1 year high of $18.70. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.57. The business's 50 day moving average is $12.89 and its two-hundred day moving average is $11.41.
Institutional Trading of R1 RCM
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC bought a new position in R1 RCM in the 3rd quarter valued at $36,000. ANTIPODES PARTNERS Ltd boosted its position in R1 RCM by 429.5% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider's stock valued at $59,000 after purchasing an additional 4,561 shares in the last quarter. Salem Investment Counselors Inc. bought a new stake in R1 RCM during the fourth quarter valued at about $61,000. Van ECK Associates Corp boosted its position in R1 RCM by 20.5% during the fourth quarter. Van ECK Associates Corp now owns 6,141 shares of the healthcare provider's stock valued at $65,000 after purchasing an additional 1,044 shares in the last quarter. Finally, Caas Capital Management LP bought a new stake in R1 RCM during the fourth quarter valued at about $148,000. Hedge funds and other institutional investors own 61.10% of the company's stock.
Insiders Place Their Bets
In other news, President John M. Sparby sold 10,046 shares of the company's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $14.33, for a total transaction of $143,959.18. Following the sale, the president now directly owns 265,986 shares of the company's stock, valued at approximately $3,811,579.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 36.80% of the stock is currently owned by corporate insiders.
About R1 RCM
(
Get Free Report)
R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.
Featured Stories
Before you consider R1 RCM, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and R1 RCM wasn't on the list.
While R1 RCM currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
